Company Overview

Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases, and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists, and dedicated physicians.

Tvardi Therapeutics TTI-101

Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions.

The company’s lead product, TTI-101, is currently being studied in multiple clinical trials across cancer and fibrosis. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory solid tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses.

Collectively, the societal and economic impact of STAT3-dependent disease is significant. Tvardi is highly motivated to develop safe and effective small molecule inhibitors of STAT3 for use across numerous diseases.

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.